These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Interventions that induce modifications in the tumor microenvironment. Bernhard EJ Cancer Radiother; 2011 Aug; 15(5):376-82. PubMed ID: 21571567 [TBL] [Abstract][Full Text] [Related]
6. The Intersection between Tumor Angiogenesis and Immune Suppression. Rahma OE; Hodi FS Clin Cancer Res; 2019 Sep; 25(18):5449-5457. PubMed ID: 30944124 [TBL] [Abstract][Full Text] [Related]
7. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. Mittal K; Ebos J; Rini B Semin Oncol; 2014 Apr; 41(2):235-51. PubMed ID: 24787295 [TBL] [Abstract][Full Text] [Related]
8. Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy. Bai Y; Wang Y; Zhang X; Fu J; Xing X; Wang C; Gao L; Liu Y; Shi L Int J Pharm; 2019 Oct; 570():118636. PubMed ID: 31446027 [TBL] [Abstract][Full Text] [Related]
9. Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. Chen P; Bonaldo P Int Rev Cell Mol Biol; 2013; 301():1-35. PubMed ID: 23317816 [TBL] [Abstract][Full Text] [Related]
10. Cytokine network: new targeted therapy for pancreatic cancer. Matsuo Y; Takeyama H; Guha S Curr Pharm Des; 2012; 18(17):2416-9. PubMed ID: 22372505 [TBL] [Abstract][Full Text] [Related]
11. The role of cytokines in the epithelial cancer microenvironment. Wilson J; Balkwill F Semin Cancer Biol; 2002 Apr; 12(2):113-20. PubMed ID: 12027583 [TBL] [Abstract][Full Text] [Related]
12. Role of mTOR Signaling in Tumor Microenvironment: An Overview. Conciatori F; Bazzichetto C; Falcone I; Pilotto S; Bria E; Cognetti F; Milella M; Ciuffreda L Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126252 [TBL] [Abstract][Full Text] [Related]
14. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Chmielewski M; Hombach AA; Abken H Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791 [TBL] [Abstract][Full Text] [Related]
15. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets. Szebeni GJ; Vizler C; Nagy LI; Kitajka K; Puskas LG Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886105 [TBL] [Abstract][Full Text] [Related]
16. Tumor-associated macrophages as an emerging target against tumors: Creating a new path from bench to bedside. Jinushi M; Komohara Y Biochim Biophys Acta; 2015 Apr; 1855(2):123-30. PubMed ID: 25595840 [TBL] [Abstract][Full Text] [Related]
18. Tumor Vasculatures: A New Target for Cancer Immunotherapy. Liu Z; Wang Y; Huang Y; Kim BYS; Shan H; Wu D; Jiang W Trends Pharmacol Sci; 2019 Sep; 40(9):613-623. PubMed ID: 31331639 [TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid-mediated effects on angiogenesis in solid tumors. Martens B; Drebert Z J Steroid Biochem Mol Biol; 2019 Apr; 188():147-155. PubMed ID: 30654109 [TBL] [Abstract][Full Text] [Related]
20. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins. Xiang J Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]